References

1. Bansal A, et al. Institutional preparedness strategies for heart failure, durable LVAD and heart transplant patients during the COVID-19 pandemic. *J Thorac Cardiovasc Surg.* 2021;162:131-5.
2. Aslam S, Danziger-Isakov L, Luong M-L, Husain S, Silveira FP, Grossi P, et al. Guidance from the International Society of Heart and Lung Transplantation regarding the SARS CoV-2 pandemic Available at: ishlt.org/ishlt/media/documents/SARS-CoV-2-Guidance-for-Cardiothoracic-Transplant-and-VAD-centers.pdf. Accessed September 2, 2020.
3. Bakaeen FG, Gillinov AM, Roselli EE, Chikwe J, Moon MR, Adams DH, et al. Cardiac surgery and the coronavirus disease 2019 pandemic: what we know, what we do not know, and what we need to do. *J Thorac Cardiovasc Surg.* 2020;160:722-6.
4. DeFilippis EM, Farr MA, Givertz MM. Challenges in heart transplantation in the era of COVID-19. *Circulation.* 2020;141:2048-51.
5. George I, Salna M, Kobsa S, Deroo S, Krieger J, Blitzer D, et al. The rapid transformation of cardiac surgery practice in the coronavirus disease 2019 (COVID-19) pandemic: insights and clinical strategies from a center at the epicenter. *Ann Thorac Surg.* 2020;160:937-47.e2.
6. Mariani S, Hanke JS, Dogan G, Schmitt JD. Out of hospital management of LVAD patients during COVID-19 outbreak. *Artif Organs.* 2020;44:873-6.

See Article page 131.

Commentary: A pandemic blueprint for planning your act and acting your plan

Serge Kobsa, MD, PhD,^a Nir Uriel, MD,^b
Koji Takeda, MD, PhD,^a and
Hiroo Takayama, MD, PhD^a

The United States has emerged as a focal point in the coronavirus disease 2019 (COVID-19) pandemic, with more than 6.3 million cases and 190,000 deaths.¹ The aftermath against COVID-19 has not begun yet; however, there are lessons learned that should be shared to help fight with the ongoing COVID-19 pandemic and with another surge. In this issue of the *Journal*, Bansal and colleagues² bring expert opinions from their experiences at 6 US academic centers, spanning geography, size, resources, and density of infection encountered, as well as the multiple disciplines involved in the care of these complicated patients, including cardiac surgeons, cardiologists, critical care anesthesiologists, and ventricular assist device (VAD) coordinators. The best practices during crisis situations are summarized as the “4Cs”: capacity, cohort, care, and collaboration.

From the ^aDivision of Cardiac, Thoracic and Vascular Surgery, Department of Surgery; and ^bDivision of Cardiology, Department of Medicine, Columbia University Medical Center, New York, NY.

Disclosures: The authors reported no conflicts of interest.

The *Journal* policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest.

Received for publication Sept 13, 2020; revisions received Sept 13, 2020; accepted for publication Sept 15, 2020; available ahead of print Sept 18, 2020.

Address for reprints: Hiroo Takayama, MD, PhD, Columbia University Medical Center, Milstein Hospital Building, 177 Fort Washington Ave, Suite 7-435, New York, NY 10032 (E-mail: ht2225@cumc.columbia.edu).

J Thorac Cardiovasc Surg 2021;162:137-8

0022-5223/\$36.00

Copyright © 2020 by The American Association for Thoracic Surgery

<https://doi.org/10.1016/j.jtcvs.2020.09.057>

Multidisciplinary heart transplant meeting.

CENTRAL MESSAGE

Authors from 6 US institutions offer recommendations for care of heart failure, mechanical circulatory support, and heart transplant patients in a pandemic.

We also learned that readiness is the key.³ In general, patients with advanced heart failure can be divided into 2 large groups; first, patients with heart failure managed medically or waiting for heart transplantation/left VAD implantation, and second, patients who had already received heart transplantation or left VAD. We found that these patients are at high risk for significant COVID-19 disease.⁴ In this paper, we suggested that each heart failure program needs to have a comprehensive and detailed plan to take care of both types of patients. This plan should be executed at every level of the medical team. Regular and uninterrupted communication with full transparency on the current status, data analysis, and future predication further empowers the team.⁵ As an example, an analysis at our center showed that the rate of in hospital transmission in a non-COVID-19 cardiothoracic intensive care unit was extremely low. This information

was promptly disseminated among the medical teams and helped reassure the safety and effectiveness of our plan. Recently, we reported our experience across New York Presbyterian Hospitals network.⁶ Again, we concluded that having a plan and acting by the plan with transparency and communication are the key. The plan, however, is to be modified and updated through constant data and situation analysis.

As the authors astutely point out, one should not risk a patient dying from heart disease to save someone dying of COVID-19—a principle we could not agree with more. Finding the balance was not easy, though. Our program was required to understand and react to the ever-changing reality. We had to transform ourselves for the care of our patients heart failure. In retrospect, the resilience of the program was tested by this pandemic. Note that Bansal and colleagues offer no uniform protocol; each program developed protocols specific to their own program and local situation. In this context, the importance of team building in non-pandemic times cannot be underestimated, and perhaps such effort is more essential than attempting to forecast the unpredictable. It requires a true integration of multidisciplinary and collaborative behavior, visionary leadership,

and fluent communications with the governance system at multiple levels.

Many of the changes/innovations introduced during this pandemic are here to stay; telehealth, remote patient monitoring, video meetings, and more. With proper preparation, planning, and leadership, we would be better prepared next time.

References

1. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. *Lancet Infect Dis*. 2020;20:533-4.
2. Bansal A, Goldstein D, Schettler S, Pepitone S, Lima B, Pham DT, et al. Institutional preparedness strategies for heart failure patients during the COVID-19 pandemic. *J Thorac Cardiovasc Surg*. 2021;162:131-5.
3. George I, Salna M, Kobsa S, Deroo S, Krieger J, Blitzer D, et al. The rapid transformation of cardiac surgery practice in the coronavirus disease 2019 (COVID-19) pandemic: insights and clinical strategies from a center at the epicenter. *Ann Thorac Surg*. 2020;110:1108-18.
4. Latif F, Farr MA, Clerkin KJ, Habal MV, Takeda K, Naka Y, et al. Characteristics and outcomes of recipients of heart transplant with coronavirus disease 2019. *JAMA Cardiol*. May 13, 2020 [Epub ahead of print].
5. Hastie J, Sutherland L, Takayama H, et al. Anesthesiologists as perioperative leaders. *Int Anesthesiol Clin*. 2020;58:58-63.
6. Sayer G, Horn EM, Farr MA, Axsom K, Kleet A, Gjerde C, et al. Transition of a large tertiary heart failure program in response to the COVID-19 pandemic: changes that will endure. *Circ Heart Fail*. 2020;13:e007516.

See Article page 131.

Commentary: Moving forward, looking back: Lessons from coronavirus disease 2019 (COVID-19) for preparedness in advanced heart failure programs

Scott C. Silvestry, MD

The coronavirus disease 2019 (COVID-19) pandemic impacted medical care profoundly, through the eclipsing

Scott C. Silvestry, MD

CENTRAL MESSAGE

MCS and heart transplant programs adapted strategically and uniquely in a variety of ways to the impact of COVID-19.

resource needs of critically ill surgery patients and through the necessary changes in medical care resulting from social distancing and limits on in-person care.

From the AdventHealth Transplant Institute, AdventHealth Orlando, Orlando, Fla.

Disclosures: The author reported no conflicts of interest.

The *Journal* policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest.

Received for publication Sept 1, 2020; revisions received Sept 1, 2020; accepted for publication Sept 2, 2020; available ahead of print Sept 9, 2020.

Address for reprints: Scott C. Silvestry, MD, AdventHealth Transplant Institute, AdventHealth Orlando, Orlando, FL 32804 (E-mail: Scott.Silvestry.MD@AdventHealth.com).

J Thorac Cardiovasc Surg 2021;162:138-9

0022-5223/\$36.00

Copyright © 2020 Published by Elsevier Inc. on behalf of The American Association for Thoracic Surgery

<https://doi.org/10.1016/j.jtcvs.2020.09.011>